NIH backs study of good/bad cholesterol combination treatment

Share this article:
The National Institutes of Health has agreed to fund a large clinical test to determine whether raising good cholesterol with a niacin-based drug, while lowering bad cholesterol with a statin, can prevent more heart disease than a statin alone, The Wall Street Journal reported today.
Previous small clinical tests have indicated that high levels of good cholesterol, or HDL cholesterol, can provide additional levels of protection. The theory has fueled development of drugs to raise HDL levels. Pfizer is spending more than $600 million on clinical tests of a combination of its best-selling blockbuster Lipitor and torcetrapib, an experimental drug to raise HDL levels.
The six-year study is expected to involve 3,300 patients, with about a third of them women. To qualify, the subjects must have existing cardiovascular disease and be candidates for drug therapy. Patients will receive either simvastatin, the generic name for Merck's Zocor, or simvastatin plus Niaspan, an extended-release form of niacin available by prescription from Kos Pharmaceuticals.
The NIH's National Heart, Lung and Blood Institute is expected to provide about $22 million in funding for the study and administer about $20 million in unrestricted funding from KOS. Some 50 to 60 clinical sites in the U.S. and Canada are expected to enroll patients in the study to begin in November.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.